Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporti...

Descripción completa

Detalles Bibliográficos
Autores principales: Domachowske, Joseph B, Chang, Yue, Atanasova, Victoria, Cabañas, Fernando, Furuno, Kenji, Nguyen, Kim A, Banu, Irfana, Kubiak, Robert J, Leach, Amanda, Mankad, Vaishali S, Shroff, Manish, Takas, Therese, Villafana, Tonya, Wählby Hamrén, Ulrika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583/
https://www.ncbi.nlm.nih.gov/pubmed/37466917
http://dx.doi.org/10.1093/jpids/piad052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583/
https://www.ncbi.nlm.nih.gov/pubmed/37466917
http://dx.doi.org/10.1093/jpids/piad052

Ejemplares similares